Oct 2026· The European Research Journal· pp. 1-11· 0 citations· 2 references
TL;DR
Postinjury agmatine rescued 6-OHDA-induced viability loss, but sequential MitoTr followed by agmatine caused an additional marked reduction in viability rather than synergistic neuroprotection, underscoring the need for optimized protocols and nonmalignant models.
Abstract
Objective: Parkinson disease (PD) involves dopaminergic neuron loss from mitochondrial dysfunction and oxidative stress. We investigated the combined, sequential effects of mesenchymal stem cell–derived mitochondrial transplantation (MitoTr) and pharmacological agmatine modulation in a PD–like undifferentiated SH-SY5Y cellular model.
Methods: Undifferentiated SH-SY5Y cells were exposed to 6-hydroxydopamine (6-OHDA; 350 μM) for 24 hours and sequentially treated with mitochondria (5 or 10 μg/mL) and agmatine (100 μM; 2 hours post-MitoTr). Cell viability was assessed via MTT assays (n = 8 independent experiments). Total-lysate cytochrome c ELISA (n = 3) and Western blots for DJ-1, REDD1, and α-synuclein (n = 4) were performed across 4 core groups.
Results: 6-OHDA significantly reduced viability compared with Control (mean [SEM], 0.50 [0.05] vs 1.00 [0.04]; P < .001); postinjury agmatine restored it to near-control levels (mean [SEM], 0.97 [0.20]; P < .001\) vs 6-OHDA), while agmatine alone had no effect (P > .99). Conversely, MitoTr-containing groups showed significantly lower viability than Control, Agmatine, and Agmatine + 6-OHDA groups (P < .001). Most MitoTr arms fell significantly below 6-OHDA alone (P < .05), except the 5 μg/mL triple group (P = .13). Expression of DJ-1, REDD1, and α-synuclein decreased numerically relative to Control without statistical significance (P > .05). Total-lysate cytochrome c was significantly elevated only in the triple-combination group compared with the Control group (mean [SEM], 36.01 [3.65] versus 22.63 [1.08] ng/mL; P = .03).
Conclusions: Postinjury agmatine rescued 6-OHDA-induced viability loss, but sequential MitoTr followed by agmatine caused an additional marked reduction in viability rather than synergistic neuroprotection. Molecular alterations remained exploratory and nonsignificant. This MitoTr-associated loss may reflect antiproliferative effects in neuroblastoma-derived cells, underscoring the need for optimized protocols and nonmalignant models.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons and associated with both genetic and environmental factors. Among environmental agents, the fungicide mancozeb (MZ) has gained attention due to its potential to induce neuronal damage. However, the mechanisms un...
Suzana da Silva, Ana Luiza dos Praseres de Souza, Natali Silva Cardoso et al.· ACS Omega· 0 citations
Introduction Icariside II (ICS II), a major bioactive flavonoid metabolite from Epimedium, has been reported to exert neuroprotective effects, but its role in regulating mitochondrial dysfunction-related neuronal injury in Alzheimer’s disease (AD) has not been fully clarified. Methods In this study, we administered ICS...
Si-Yu Shan, Jia-Ming Bai, Yu Tian et al.· Frontiers in Pharmacology· 0 citations
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by the loss of dopaminergic neurons and impaired mitochondrial dynamics. Salidroside (SAL), a natural compound extracted from Rhodiola rosea, possesses antioxidative and anti-inflammatory properties, yet its role in regulating mitochondrial fis...
Rui-Xi Zhao, Li-Fang Chen, Xin Li et al.· International Journal of Neu...· 0 citations
Aging leads to a progressive impairment of mitochondrial function and/or increased oxidative damage has been suggested to play critical roles in the pathogenesis of the neurodegenerative diseases. Brains have a high metabolic rate and relatively low capacity for cellular regeneration, nerve cells in brain area are part...
Maneerat Itsaramongkhonkan, Wenika Benjapong, J. Sirivarasai et al.· Thai Journal of Toxicology· 0 citations
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the nigrostriatal pathway. Current treatments for PD primarily provide symptomatic relief through dopamine replacement; however, no neuroprotective drugs are currently clinically available. Our prev...
Yasuhiro Matsuura, Takayuki Manabe, Tomoko Ohkubo et al.· Biological and Pharmaceutica...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.